Financial Assistance

FINANCIAL ASSISTANCE

Patient Support Brochure (English)

FINANCIAL ASSISTANCE

Patient Support Brochure (English)

FINANCIAL ASSISTANCE

Patient Support Brochure (English)

People preparing food together in a home kitchen setting

People featured on this page are taking BRIUMVI and have been compensated by TG Therapeutics for their time. For use in adults only.

People featured on this page are taking BRIUMVI and have been compensated by TG Therapeutics for their time.
For use in adults only.

What is the BRIUMVI Copay Assistance Program?

BRIUMVI® (ublituximab-xiiy) Copay Assistance Program logo

$0 copay logo

Treatment Costs

Eligible patients may pay as little as $0 copay* per BRIUMVI treatment up to the annual maximum of $20,000

Infusion and Administration Costs

Eligible patients who have out-of-pocket costs may be covered up to $550 for the first infusion and then up to $350 per infusion thereafter

You may be eligible if you…

  • Have commercial insurance
  • Are 18 years of age or older

Click here for full BRIUMVI Copay Program Terms and Conditions

*For commercially insured patients only. Other eligibility requirements apply. Visit www.briumvicopayterms.com for full terms and conditions.

Other financial assistance options

If you are not eligible for the BRIUMVI Copay Assistance Program, you may qualify for these other financial assistance options.

BRIUMVI Patient Assistance Program

If you do not have insurance or are underinsured and meet certain financial eligibility criteria, you may qualify for the BRIUMVI Patient Assistance Program. You can ask your Case Manager for more information about the BRIUMVI Patient Assistance Program.

Third-party charitable organizations†

If you are not eligible for any BRIUMVI financial assistance programs, there are third-party charitable organizations that may be able to help.

†TG Therapeutics is not affiliated with these organizations.  Each organization sets its own eligibility and application process and is independent from TG Therapeutics.  TG Therapeutics makes no guarantee a patient will receive any type of assistance or that funding is available.  Please contact each organization directly to obtain more information.

BRIUMVI Patient Support

BRIUMVI Patient Support offers a flexible program designed to support the treatment journey.

Patient Support
BRIUMVI® (ublituximab-xiiy) Patient Support logo
Professional woman working on her laptop

Hear from the thousands who are taking on RMS with BRIUMVI

 

Discover how people living with RMS have included BRIUMVI in their treatment journey.

Learn More
Three smiling people seated at an outdoor table

Hear from the thousands who are taking on RMS with BRIUMVI

Three smiling people seated at an outdoor table

Discover how people living with RMS have included BRIUMVI in their treatment journey.

Learn More

Hear from the thousands who are taking on RMS with BRIUMVI

Discover how people living with RMS have included BRIUMVI in their treatment journey.

Learn More
Three smiling adults share a meal at an outdoor table

INDICATION AND IMPORTANT
SAFETY INFORMATION

Who should not receive BRIUMVI?

Do not receive BRIUMVI if you have an active hepatitis B virus (HBV) infection.

Do not receive BRIUMVI if you have had a life-threatening allergic reaction to BRIUMVI. Tell your healthcare provider if you have had an allergic reaction to BRIUMVI or any of its ingredients in the past.

What is the most important information I should know
about BRIUMVI?

BRIUMVI can cause serious side effects, including:

  • Infusion reactions: Infusion reactions are one of the most common side effects of BRIUMVI, which can be serious and may require you to be hospitalized. You will be monitored during your infusion and may be monitored after each infusion of BRIUMVI for signs and symptoms of an infusion reaction. Tell your healthcare provider if you get any of these symptoms:
    • fever
    • chills
    • headache
    • flu-like symptoms
    • fast heartbeat
    • hives
    • itchy skin
    • dizziness
    • feeling faint
    • swelling of tongue or throat
    • trouble breathing
    • wheezing
    • nausea
    • abdominal pain
    • throat irritation
    • redness of the face or skin

These infusion reactions can happen over 24 hours after your infusion. It is important that you call your healthcare provider right away if you get any of the signs or symptoms listed above after each infusion. If you get an infusion reaction, your healthcare provider may need to stop or slow down the rate of your infusion.

  • Infection:
    • Infections are a common side effect, and upper respiratory tract infections are one of the most common side effects of BRIUMVI. BRIUMVI increases your risk of getting infections caused by bacteria or viruses that may be life-threatening or cause death. Tell your healthcare provider if you have an infection or have any of the following signs of infection including fever, chills, a cough that does not go away, or painful urination. Your healthcare provider should delay your treatment with BRIUMVI until your infection is gone.
    • Hepatitis B virus (HBV) reactivation: Before starting treatment with BRIUMVI, your healthcare provider will do blood tests to check for hepatitis B viral infection. If you have ever had hepatitis B virus infection, the hepatitis B virus may become active again during or after treatment with BRIUMVI. Hepatitis B virus becoming active again (called reactivation) may cause serious liver problems including liver failure or death. Your healthcare provider will monitor you if you are at risk for hepatitis B virus reactivation during treatment and after you stop receiving BRIUMVI.
    • Weakened immune system: BRIUMVI taken before or after other medicines that weaken the immune system could increase your risk of getting infections.
    • Progressive Multifocal Leukoencephalopathy (PML): PML is a rare, serious brain infection caused by a virus that may get worse over days or weeks. PML can result in death or severe disability. PML has been reported with BRIUMVI. Tell your healthcare provider right away if you have any new or worsening neurologic signs or symptoms. These symptoms may include weakness on one side of your body, loss of coordination in arms and legs, vision problems, changes in thinking and memory which may lead to confusion, and personality changes.
  • Low immunoglobulins: BRIUMVI may cause a decrease in some types of antibodies. Your healthcare provider will do blood tests to check your blood immunoglobulin levels.

Before receiving BRIUMVI, tell your healthcare provider about all of your medical conditions, including if you:

  • have or think you have an infection.
  • take or plan to take medicines that affect your immune system. These medicines may increase your risk of getting an infection.
  • have ever had hepatitis B or are a carrier of the hepatitis B virus.
  • have a history of liver problems.
  • have had a recent vaccination or are scheduled to receive any vaccinations.
    • You should receive any required ‘live’ or ‘live-attenuated’ vaccines at least 4 weeks before you start treatment with BRIUMVI. You should not receive ‘live’ or ‘live-attenuated’ vaccines while you are being treated with BRIUMVI and until your healthcare provider tells you that your immune system is no longer weakened.
    • When possible, you should receive any ‘non-live’ vaccines at least 2 weeks before you start treatment with BRIUMVI. If you would like to receive any non-live vaccines while you are being treated with BRIUMVI, talk to your healthcare provider.
    • If you have a baby and you received BRIUMVI during your pregnancy, it is important to tell your baby’s healthcare provider about receiving BRIUMVI so they can decide when your baby should be vaccinated.
  • are pregnant, think that you might be pregnant, or plan to become pregnant. It is not known if BRIUMVI will harm your unborn baby. You should use birth control (contraception) during treatment with BRIUMVI and for at least 6 months after your last infusion of BRIUMVI. Talk with your healthcare provider about what birth control method is right for you during this time.
  • are breastfeeding or plan to breastfeed. It is not known if BRIUMVI passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take BRIUMVI.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of BRIUMVI?

BRIUMVI may cause serious side effects, including:

• See “What is the most important information I should know about BRIUMVI?”

• Liver damage. BRIUMVI may cause liver damage. Your healthcare provider will do blood tests to check your liver before you start BRIUMVI and while you take BRIUMVI if needed. Tell your healthcare provider right away if you have any symptoms of liver damage, such as:

    • yellowing of the skin and eyes (jaundice)
    • nausea
    • vomiting
    • unusual darkening of the urine
    • feeling tired or weak

The most common side effects of BRIUMVI include:

  • Infusion reactions, upper and lower respiratory tract infections, herpes infections, extremity pain, insomnia, and fatigue.

These are not all the possible side effects of BRIUMVI. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to TG Therapeutics at 1-877-TGTXINC (1-877-848-9462).

For more important information, go to www.briumvi.com or call 1-833-BRIUMVI (1-833-274-8684).

Indication

BRIUMVI is a prescription medication used to treat adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapse-remitting disease, and active secondary progressive disease.

Stay in the know

Sign up to receive the latest updates and resources for BRIUMVI

Sign up

Join us for a Multiple Sclerosis (MS) educational event near you

Register now
Important Safety Information
Who should not receive BRIUMVI?
  • Do not receive BRIUMVI if you have an active hepatitis B virus (HBV) infection.
  • Do not receive BRIUMVI if you have had a life-threatening allergic reaction to BRIUMVI. Tell your healthcare provider if you have had an allergic reaction to BRIUMVI or any of its ingredients in the past.
 Indication
BRIUMVI is a prescription medication used to treat adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapse-remitting disease, and active secondary progressive disease.

Click or scroll to see IMPORTANT SAFETY INFORMATION AND INDICATION

Important Safety Information
Who should not receive BRIUMVI?
  • Do not receive BRIUMVI if you have an active hepatitis B virus (HBV) infection.
  • Do not receive BRIUMVI if you have had a life-threatening allergic reaction to BRIUMVI. Tell your healthcare provider if you have had an allergic reaction to BRIUMVI or any of its ingredients in the past.